0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Poor (DB RCT) -25% 1.25 [0.15-10.5] death 2/8 1/5 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.85 Late treatment -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk All studies -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk 1 tenecteplase COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.85 Effect extraction pre-specified(most serious outcome) Favors tenecteplase Favors control
Tenecteplase is a recombinant tissue plasminogen activator (tPA) and fibrinolytic agent that dissolves blood clots by converting plasminogen to plasmin. Recent:
Poor.
Feb 16
2024
 Poor et al., Cureus, doi:10.7759/cureus.54298 Tenecteplase With Concomitant Anticoagulation for Acute Respiratory Failure in Patients With COVID-19: A Randomized Controlled Trial
25% higher mortality (p=1), 38% lower progression (p=0.59), and 15% shorter hospitalization (p=0.82). RCT 13 hospitalized COVID-19 patients with acute respiratory failure showing no significant difference in mortality or respiratory outcomes with tenecteplase plus heparin versus placebo plus heparin. At 28 days, 63% of tenecteplase patien..